| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
- The targets of Beta-asarone are long non-coding RNA (lncRNA) MALAT1 and α-synuclein protein [1]
|
|---|---|
| ln Vitro |
- Cell Viability Assay: In human neuroblastoma SH-SY5Y cells induced by 1-methyl-4-phenylpyridinium (MPP⁺), treatment with Beta-asarone (5, 10, 20 μM) for 24 hours significantly increased cell viability (detected by MTT assay). The cell viability in the 20 μM Beta-asarone group was increased by approximately 35% relative to the model group [1]
- Apoptosis Inhibition: Flow cytometry analysis showed that Beta-asarone (5, 10, 20 μM) reduced MPP⁺-induced apoptosis of SH-SY5Y cells. The apoptotic rate in the 20 μM Beta-asarone group was decreased from ~45% (model group) to ~18% [1] - Protein and lncRNA Regulation: Western blot results demonstrated that Beta-asarone (5, 10, 20 μM) dose-dependently inhibited α-synuclein protein overexpression induced by MPP⁺; qPCR analysis showed that Beta-asarone (5, 10, 20 μM) significantly downregulated the expression level of lncRNA MALAT1 in MPP⁺-injured SH-SY5Y cells, with a maximum downregulation of ~60% in the 20 μM group [1] |
| ln Vivo |
- Behavioral Improvement: In C57BL/6 mice with MPTP-induced Parkinson's disease (PD), intraperitoneal injection of Beta-asarone (20, 40 mg/kg/day) for 14 days significantly improved PD-related motor deficits. In the rotarod test, the latency to fall of mice in the 40 mg/kg Beta-asarone group was extended from ~15 seconds (model group) to ~40 seconds; in the pole test, the time to climb down the pole was shortened from ~25 seconds (model group) to ~12 seconds [1]
- Dopaminergic Neuron Protection: Immunohistochemical staining of mouse midbrain sections showed that Beta-asarone (20, 40 mg/kg/day) increased the number of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra pars compacta (SNpc) of MPTP-induced PD mice. The number of TH-positive neurons in the 40 mg/kg Beta-asarone group was increased by ~50% compared with the model group [1] - α-synuclein and MALAT1 Regulation: Western blot and qPCR analyses of mouse midbrain tissues revealed that Beta-asarone (20, 40 mg/kg/day) dose-dependently inhibited MPTP-induced α-synuclein protein accumulation and downregulated lncRNA MALAT1 expression [1] |
| Cell Assay |
- SH-SY5Y Cell Culture and Treatment: SH-SY5Y cells were cultured in DMEM medium containing 10% fetal bovine serum at 37°C with 5% CO₂. Cells were first treated with 500 μM MPP⁺ for 24 hours to establish the PD cell model, then incubated with Beta-asarone (5, 10, 20 μM) for another 24 hours. A normal control group (without MPP⁺ and Beta-asarone) and a model group (with MPP⁺ but without Beta-asarone) were set up in parallel [1]
- MTT Assay for Cell Viability: After treatment, cells were incubated with MTT solution (5 mg/mL) for 4 hours at 37°C. The supernatant was discarded, and dimethyl sulfoxide (DMSO) was added to dissolve the formazan crystals. The absorbance at 490 nm was measured with a microplate reader to calculate cell viability [1] - Western Blot for α-synuclein: Cells were lysed with RIPA buffer to extract total protein, and protein concentration was determined by BCA assay. Equal amounts of protein were separated by SDS-PAGE, transferred to PVDF membranes, and incubated with primary antibodies against α-synuclein and β-actin (internal reference) overnight at 4°C. After incubation with secondary antibodies, the protein bands were visualized by chemiluminescence, and the gray value of bands was analyzed to quantify α-synuclein expression [1] - qPCR for MALAT1: Total RNA was extracted from cells using TRIzol reagent, and reverse-transcribed into cDNA. qPCR was performed with specific primers for MALAT1 and GAPDH (internal reference) using SYBR Green Master Mix. The relative expression level of MALAT1 was calculated by the 2⁻ΔΔCt method [1] |
| Animal Protocol |
- Animal Model Establishment: Male C57BL/6 mice (8–10 weeks old) were used to establish the PD model by intraperitoneal injection of MPTP hydrochloride (20 mg/kg/day) for 5 consecutive days. A normal control group was injected with equal volume of saline [1]
- Drug Administration: Starting from the 1st day after MPTP injection, mice in the drug groups were given intraperitoneal injection of Beta-asarone at doses of 20 mg/kg/day and 40 mg/kg/day, respectively; the normal control group and model group were injected with equal volume of saline (containing 0.1% DMSO to dissolve Beta-asarone). The administration lasted for 14 consecutive days [1] - Sample Collection and Detection: After the last administration, mice were subjected to behavioral tests (rotarod test and pole test). Then, mice were sacrificed by cervical dislocation, and the midbrain tissues (including SNpc) were dissected. Part of the midbrain tissue was fixed with 4% paraformaldehyde for immunohistochemical staining (TH antibody), and the remaining tissue was used for Western blot (α-synuclein detection) and qPCR (MALAT1 detection) [1] |
| References | |
| Additional Infomation |
Asarone is a phenylpropanoid compound with a benzene ring substituted with methoxy groups at positions 1, 2, and 4, and with a propen-1-yl group at position 5. It has been isolated from plants of the genus Acorus. It is a plant metabolite. It belongs to the phenylpropanoid class of compounds, specifically the methoxybenzene and alkenylbenzene groups.
β-Asarone has been reported in Perilla frutescens, Asarum heterotropoides, and other organisms with relevant data. See also: Acorus calamus root (partial). - Mechanism of action: β-Asarone exerts a protective effect against MPTP/MPP⁺-induced Parkinson's disease by downregulating the expression of lncRNA MALAT1, thereby inhibiting the abnormal accumulation of α-synuclein. This mechanism can reduce neurotoxicity, inhibit neuronal apoptosis, and protect dopaminergic neurons in the substantia nigra [1] - Research significance: This study provides experimental evidence for β-asarone as a potential therapeutic drug for Parkinson's disease and highlights that lncRNA MALAT1 and α-synuclein are key targets for the treatment of Parkinson's disease [1] |
| Molecular Formula |
C12H16O3
|
|---|---|
| Molecular Weight |
208.2536
|
| Exact Mass |
208.109
|
| CAS # |
5273-86-9
|
| PubChem CID |
5281758
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
296.0±0.0 °C at 760 mmHg
|
| Flash Point |
107.7±23.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.526
|
| LogP |
2.98
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
203
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1=C([H])C(=C(C([H])=C1/C(/[H])=C(\[H])/C([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H]
|
| InChi Key |
RKFAZBXYICVSKP-WAYWQWQTSA-N
|
| InChi Code |
InChI=1S/C12H16O3/c1-5-6-9-7-11(14-3)12(15-4)8-10(9)13-2/h5-8H,1-4H3/b6-5-
|
| Chemical Name |
1,2,4-trimethoxy-5-[(Z)-prop-1-enyl]benzene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~480.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (13.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (13.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.75 mg/mL (13.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8019 mL | 24.0096 mL | 48.0192 mL | |
| 5 mM | 0.9604 mL | 4.8019 mL | 9.6038 mL | |
| 10 mM | 0.4802 mL | 2.4010 mL | 4.8019 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
